Literature DB >> 2830030

Sites of topoisomerase I action on X. laevis ribosomal chromatin: transcriptionally active rDNA has an approximately 200 bp repeating structure.

V Culotta1, B Sollner-Webb.   

Abstract

The sites at which topoisomerase I interacts with the transcriptionally active ribosomal chromatin of Xenopus oocytes were mapped by treating oocyte nuclei first with camptothecin to stabilize topoisomerase I-rDNA reaction intermediates, and then with SDS to resolve these adducts as protein-linked nicks in the DNA. Strikingly, the topoisomerase I sites are concentrated in the region encoding the 18S, 5.8S, and 28S rRNAs, where they are spaced with a periodicity of approximately 200 nucleotides. Plasmid rDNA that has assembled into a nucleoprotein structure in an oocyte nuclear extract yields this same restricted pattern of sites, while rDNA that is not in a chromatin structure exhibits a continuum of topoisomerase I cleavages. Thus, the approximately 200 bp spacing of sites of topoisomerase I interaction evidently reflects rDNA chromatin structure. These results indicate that the active rRNA genes are organized into nucleosome-like arrays, with topoisomerase I located in the linker regions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2830030     DOI: 10.1016/0092-8674(88)90471-0

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  22 in total

1.  Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.

Authors:  D Strumberg; A A Pilon; M Smith; R Hickey; L Malkas; Y Pommier
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

2.  Ribosomal gene clusters are uniquely proportioned between open and closed chromatin structures in both tomato leaf cells and exponentially growing suspension cultures.

Authors:  A Conconi; J M Sogo; C A Ryan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

3.  Topoisomerase I is preferentially associated with normal SV40 replicative intermediates, but is associated with both replicating and nonreplicating SV40 DNAs which are deficient in histones.

Authors:  J J Champoux
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

4.  In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.

Authors:  C Pondarré; D Strumberg; A Fujimori; R Torres-León; Y Pommier
Journal:  Nucleic Acids Res       Date:  1997-10-15       Impact factor: 16.971

5.  Topoisomerase I is associated with the regulatory region of transcriptionally active SV 40 minichromosomes.

Authors:  Y S Vassetzky; V V Bakayev; A G Kalandadze; S V Razin
Journal:  Mol Cell Biochem       Date:  1990-06-25       Impact factor: 3.396

6.  Structural analysis of mouse rDNA: coincidence between nuclease hypersensitive sites, DNA curvature and regulatory elements in the intergenic spacer.

Authors:  G Längst; T Schätz; J Langowski; I Grummt
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

7.  Mapping in vivo topoisomerase I sites on simian virus 40 DNA: asymmetric distribution of sites on replicating molecules.

Authors:  S E Porter; J J Champoux
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

8.  Topoisomerase I sites cluster asymmetrically at the ends of the simian virus 40 core origin of replication.

Authors:  S Tsui; M E Anderson; P Tegtmeyer
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  Enrichment and depletion of Hela topoisomerase I recognition sites among specific types of DNA elements.

Authors:  C Perez-Stable; C C Shen; C K Shen
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

10.  Binding of sequences from the 5'- and 3'-nontranscribed spacers of the rat rDNA locus to the nucleolar matrix.

Authors:  E Stephanova; R Stancheva; Z Avramova
Journal:  Chromosoma       Date:  1993-03       Impact factor: 4.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.